HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer
Authors:
- Margaret Gardiner-GardenMGMargaret Gardiner-Garden
- Gabriele MöllerGMGabriele Möller
- James G. KenchJKJames G. Kench
- Phillip D. StrickerPSPhillip D. Stricker
- Jerzy AdamskiJAJerzy Adamski
- Vanessa M. HayesVHVanessa M. Hayes
- 1 March 2009
- journal article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 301 (1-2) , 89-96
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Expression of Enzymes Involved in Estrogen Metabolism in Human ProstateJournal of Histochemistry & Cytochemistry, 2006
- A molecular correlate to the Gleason grading system for prostate adenocarcinomaProceedings of the National Academy of Sciences, 2006
- Molecular markers of prostate cancer outcomeEuropean Journal of Cancer, 2005
- Peroxisomal branched chain fatty acid ?-oxidation pathway is upregulated in prostate cancerThe Prostate, 2004
- Gene expression analysis of prostate cancersMolecular Carcinogenesis, 2002
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Evolution of 17β-HSD type 4, a multifunctional protein of β-oxidationMolecular and Cellular Endocrinology, 2001
- Hormonal carcinogenesisCarcinogenesis, 2000
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998